Navigation Links
Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
Date:9/12/2008

NANJING, China, Sept. 12 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announces the promotions of Mr. Jindong Zhou and Mr. Xiaojin Yin to Executive Vice President and Senior Vice President, respectively, and the appointment of Mr. Qingsen Li to the newly created position of Vice President of Human Resources.

Mr. Jindong Zhou joined Simcere in 1994 and has over twenty years of experience in the pharmaceutical industry. Prior to his promotion, he served as Vice President of Manufacturing overseeing several GMP manufacturing plants. As Executive Vice President, he broadens his responsibilities beyond manufacturing to include sales and marketing and other executive office support.

Mr. Xiaojin Yin joined Simcere in 2000, and as Vice President of R&D he introduced both Bicun and Endu to the Company together with many other pipeline products. In his new role as Senior Vice President of R&D, he will continue to oversee the Company's R&D activities with a focus on bringing more pipeline products and senior R&D professionals to the Company.

Mr. Qingsen Li joins Simcere from Taikang Insurance Co. Ltd. where he was General Manager of Training and Human Resources. Prior to Taikang, Mr. Li held the position of Vice President and Director of Human Resources at Novartis China.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere, commented: "We are delighted to promote Jindong Zhou and Xiaojin Yin to new positions with increased management responsibilities. These executives have made many valuable contributions to Simcere and we know their strong leadership and execution capabilities will continue to help Simcere achieve further growth."

Mr. Ren added: "We are also pleased to welcome Qingsen Li to our management team. His vast experience with both local Chinese and multinational companies will bring human resources at Simcere to a new level and reinforces our commitment in bringing onboard the best quality talent into the Company."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
2. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
3. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
4. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
5. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
6. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
7. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
8. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
9. Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
10. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
11. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):